#Reflow medical trial

At the same time, the act specifies the group of people who can use CBD as an option for their medical condition. The act allows certain people to use CBD oil with a THC concentration which is not higher than 5.

#Reflow medical trial

'Their ability to perform this study during a global pandemic and achieve this milestone shows their commitment and dedication to advancing technologies in the CLI space. SAN CLEMENTE, Calif.- ( BUSINESS WIRE )- Reflow Medical, Inc., a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease. In 2015, the act which is called HB1 was passed. 'On behalf of the team here at Reflow, we offer sincere thanks and gratitude for the partnership with Professor Brodmann and her team,' commented Isa Rizk, CEO and Co-founder of Reflow Medical. Teo Jimenez, Reflow Medical’s Senior Vice President of Research and Development said, 'Finishing enrollment in this study continues to highlight the versatility and safety of the Spur device with multiple drug-coated platforms.' The device is also intuitive and easy to use.' 'It’s eye-opening, how the vessel responds. 'We were impressed from the start with the acute luminal gain we were able to achieve,' says Marianne Brodmann, MD, who is a Professor and Vascular Specialist at the Medical University of Graz, Austria, and the Principal Investigator for the study. The system is then recaptured and removed, without leaving anything behind. Engineered to fulfill an unmet clinical need in treating patients suffering from Critical Limb Ischemia (CLI), the Temporary Spur Stent System consists of a unique, retrievable nitinol stent system with radially expandable spikes or 'spurs' designed to create channels for increased uptake of antiproliferative drugs ('limus' based) into the vessel wall.